ResearcherNational Taiwan UniversityActive in the last 2 years

Shih‐Hung Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8572-4977; OpenAlex author ID A5031833158. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jfma.2025.02.035 ↗
Incorporating nivolumab with preceded gemcitabine and S-1 chemotherapy for patients of metastatic pancreatic cancer: a pilot study. Co-author DOI 10.62347/njox8790 ↗
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Co-author DOI 10.1016/j.ejca.2019.10.023 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yan‐Shen Shan · 2 shared papers, 2020–2026 · strength 0.42
- Paper Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin … DOI 10.1016/j.jfma.2025.02.035 ↗
- Paper A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adeno… DOI 10.1016/j.ejca.2019.10.023 ↗
Chien‐Jui Huang · 1 shared paper, 2026 · strength 0.32
- Paper Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin … DOI 10.1016/j.jfma.2025.02.035 ↗
Sung‐Hsin Kuo · 1 shared paper, 2026 · strength 0.32
- Paper Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin … DOI 10.1016/j.jfma.2025.02.035 ↗
Kun‐Huei Yeh · 1 shared paper, 2026 · strength 0.32
- Paper Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin … DOI 10.1016/j.jfma.2025.02.035 ↗
Yulin Lin · 1 shared paper, 2020 · strength 0.11
- Paper A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adeno… DOI 10.1016/j.ejca.2019.10.023 ↗
Nai‐Jung Chiang · 1 shared paper, 2020 · strength 0.11
- Paper A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adeno… DOI 10.1016/j.ejca.2019.10.023 ↗
Jen‐Shi Chen · 1 shared paper, 2020 · strength 0.11
- Paper A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adeno… DOI 10.1016/j.ejca.2019.10.023 ↗
Chiun Hsu · 1 shared paper, 2020 · strength 0.11
- Paper A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adeno… DOI 10.1016/j.ejca.2019.10.023 ↗
Kelvin K. Tsai · 1 shared paper, 2020 · strength 0.11
- Paper A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adeno… DOI 10.1016/j.ejca.2019.10.023 ↗
Li‐Tzong Chen · 1 shared paper, 2020 · strength 0.11
- Paper A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adeno… DOI 10.1016/j.ejca.2019.10.023 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.